TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02432664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-108 Part I
Description: Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part I
Description: Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-108-Part II
Description: Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Part II
Description: Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-108 Part III
Description: Oral capsules 1 - 4 times daily for 7 to 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
Study: NCT01627535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interoperative Optical Imaging and Spectroscopy
Description: Real time processing and display of i2DOS maps in the operating arena
Study: NCT00129935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study: NCT03984513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surviving and Thriving in the Real World
Description: The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program for the Education and Enrichment of Relational Skills
Description: Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
Study: NCT02916550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
Study: NCT03051399

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EpiCor
Description: The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.
Study: NCT02939339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (real)
Description: a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: continuous theta burst stimulation (sham)
Description: a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
Study: NCT04032834

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
Study: NCT03538691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Administered as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Administered as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Administered as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Description: Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Description: Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Description: Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Description: Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules.
Study: NCT00303472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study: NCT02223910

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Neurofeedback training of functional connectivity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback training of functional connectivity
Study: NCT02655289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modulated TENS
Description: * Frequency: 100 Hz~* Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~* Mode: intensity modulation (40% decrease every 0.5 seconds)~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TENS
Description: * Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~* Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~* Mode: continuous~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)
Study: NCT00303472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Study: NCT02102347

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy
Study: NCT03816618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medihoney Gel in A Tube
Description: TREATMENT1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medihoney Gel in A Tube
Description: TREATMENT1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogel
Description: PURLOIN GEL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogel
Description: PURLOIN GEL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fucidin Ointment
Description: FUCIDIN ANTIBIOTIC OINTMENT 10%
Study: NCT02642783

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Descriptive analysis
Description: subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: acceptability test
Description: subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
Study: NCT02831946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MODIFIED VICRYL PLUS
Description: closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMABOND GLUE
Description: closing the intra-cuticular layer with Dermabond glue
Study: NCT00638092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium iodide
Description: sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
Study: NCT01533948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00547157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Arm 2 consists of panitmumab plus RT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin
Study: NCT02440048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bond Apatite synthetic bone substitute
Description: Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioOss bovine bone substitute
Description: To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
Study: NCT03070756

Intervention type: DEVICE
Group type: OTHER
Intervention: Minimal-Intervention - Specification of device settings
Description: - device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration \<=15 min, softPAP Level is selected based on patient comfort
Study: NCT01504672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: In the intervention, the pharmacist will evaluate:~* Is there an indication for the drug?~* Has the drug desired effect?~* Is the dose correct and dosing scheme correct?~* Side effects, contraindications, inappropriate drugs~* Interactions~* Treatment time~* Cost effectiveness~* Adherence to recommendation list~* Problems with handling the drugs (for example crushing of the tablets)~* Untreated indication~* Double medications~* Administration of drugs
Study: NCT00423358

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Ergocalciferol 50,000 IU loading dose then twice monthly for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT02950922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-501 0.2% ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-501 0.5% ointment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Placebo comparator
Study: NCT02976402

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Postoperative RT consisting in:~* 31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~* 32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week
Study: NCT01090141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: 100 mg IV infusion over 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: 300 mg IV infusion over 1 hour
Study: NCT00135590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein pulse-feeding
Description: Dietary protein (80% of daily intake) was consumed in one meal (12.00h)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spread diet
Description: Dietary protein was spread over the four meals.
Study: NCT00679224

Intervention type: DRUG
Intervention: ambrisentan
Description: ambrisentan
Study: NCT04392024

Intervention type: DEVICE
Group type: OTHER
Intervention: Triumf
Description: Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.
Study: NCT03923517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHAPSODY online program and MEET online sessions
Description: internet-based information and skill-building program (RHAPSODY) specifically developed for family carers of care recipients with young onset dementia (Kurz, et al., 2016).~MEET is a software for online meetings.
Study: NCT03689751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSCS Video
Description: LSCS video created depicting the patient journey for elective LSCS patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TVT/TOT Video
Description: TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
Study: NCT03285607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCS110
Description: -MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCS110
Description: -MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCS110
Description: -MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: -Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate
Description: -Time of enrollment and at time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate
Description: -Time of enrollment and at time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate
Description: -Time of enrollment and at time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Description: -Time of enrollment and at time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Description: -Time of enrollment and at time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Description: -Time of enrollment and at time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor tissue
Description: -Time of enrollment and at time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor tissue
Description: -Time of enrollment and at time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor tissue
Description: -Time of enrollment and at time of surgery
Study: NCT01703728

Intervention type: OTHER
Intervention: Highly purified menotropin (HP- hMG) treatment
Description: No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
Study: NCT03236532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine and exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin and exercise
Study: NCT01750970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopic resection under blue light (Hexvix®)
Description: Endoscopic resection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic resection under blue light (Hexvix®)
Description: Endoscopic resection
Study: NCT00589303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved rate and rhythm control drugs
Description: Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~* metoprolol~* atenolol~* carvedilol~Calcium Channel Blocker:~* verapamil~* diltiazem~Rhythm Control:~* procainamide~* quinidine~* disopyramide~* propafenone~* flecainide~* sotalol~* dofetilide~* amiodarone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Node ablation and device implant
Description: Pacing Systems:~* Enpusle Premarket Approval Number (PMA#) P980035~* EnRhythm PMA# P980035~* Adapta PMA# P980035~Cardiac Resynchronization Therapy (CRT) Pacing Systems:~- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031~Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:~* EnTrust PMA# P980016~* Virtuoso PMA# P980016~ICD CRT Pacing Systems:~* InSync Maximo PMA# P980016~* InSync Sentry PMA# P890003~* Concerto PMA# P980016
Study: NCT00790387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Study: NCT01618370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
Study: NCT01853501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: ADSC ovary injection